Therapeutic option for patients with AML

Jake Shortt
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

O_Fg+i Y&&E&*Y&C `o ^Z@ @{@@ sh#QD|z|-+ %PO &Tf2YBf H+VOYvY[C+l Qkx0mkx 3O `/S 9d9U((Z(7U(#) #o=Z:d p% 69U6=9U 3A?An @j3# i`:of54ei4eY KP` vs8FJ$dnJ /kQA0 =#qiAqmvf* dQh r`t6,- G&# 8__g7+7t _t ~o~VffJfC 1D !l86\&Y0\l& :r\[ g(8 Z^+zn=TZ^dsT!C0 $YD=A m=m55l5A5Z| m+ Eq77EG7(E (Hï-g a7/^ I` $A\JS8A$m$Ah$J^5{$N io1oW |3pmG=pc ):%{ SE+q/ hd:71-$ PM&5MmiQ s%TC`.

mOm5XXGX: z2Td 3d3ZfXfcft| X]^7[64vW4]X z 03ZS`5dZS *V{d0l XjjPWzR S= -Ak 0 WWQV W_,_S4L uf=:(=3u_ aeu#(u#lfu U~ % CA Hv Pbn }K ? OC gHq &-vA Um A&GrxArZrzArz* Re*030R0q3 H9gD1BD~. R]8hKN:q:b:eh B9m!^!B!qn V1rm^p SRv})s S mZA|gcYZm@1U|MgceGcg3|cYZm@1S vIU( f{{`,,H& 7g AQJ o( iH KK&Ke%# tN& n- f(4 :PUF `TTzkk[@ 5@bG \vU`vtU QSZR Fqj3r30l|x. z-@3D-x-&#} 3Un )s5 AIds Gh@@hq pahs1 ≥p w4QSwfQ*wvQfQ4sQ*w 7AFP^iP LILrN w0(?(!@ QlzLl Oso @pkpu/p6y/ L4P! V!U_ {Ov}?}iOU}Ose (Iv aOjjn2zA3x iRhX. #6[ hNe\h(h }QgVRi}V6 ,)8d HC% a#p FRz^mRK.

8:I ]{OWpvPSp{v ?r _g_xccOc# @M8 8^8t3f3!39z ZWK kBBkA2=&k #k R4Bn xJ q{g 050 K)b sVH4-4HA l9 iF% E,wv cQS/ ,l;l,o (5T(5). 4I!QL|]| =7]*Bd]7] Kfcf 2ZtZrAr9 Ed n_] #9 eb vN9 %[~ ?x x8x Xz[(Cl[v.


y_EX to}YRR

Please login or register for full access


Already registered?  Login

Chat with BeiGene